Beximco Pharma Regulatory News (BXP)

BEXIMCO PHARMACEUTICALS LTD.

9th May, 2014

AGM Notification

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), today announces that the 38th Annual General Meeting of the Shareholders of Beximco Pharmaceuticals Limited will be held on Saturday, the 21st June, 2014. The meeting will take place at 10.30 a.m. at Beximco Industrial Park, Sarabo, Kashimpur, Gazipur to transact the following business:

AGENDA:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended 31st December, 2013 together with reports of the Auditors and the Directors thereon.

2. To declare 10% Cash and 5% Stock Dividend.

3. To elect Directors.

4. To confirm the re-appointment of Managing Director.

5. To approve the appointment of Independent Directors.

6. To appoint Auditors for the year 2014 and to fix their remuneration.

7. To transact any other business of the Company with the permission of the Chair.

By order of the Board,

MD. ASAD ULLAH, FCS

Executive Director & Company Secretary

NOTES:

(1) The Record Date of the Company shall be on 18th May, 2014.

(2) The Shareholders whose names will appear in the Share Register of the Company or in the Depository Register on the record date i.e. 18th May, 2014, will be entitled to attend at the Annual General Meeting and to receive the dividend.

(3) A member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Registered office of the Company, not later than 48 hours before the time fixed for the meeting.

(4) Admission to the meeting room will be strictly on production of the attendance slip sent with the Notice as well as verification of signature of Member(s) and/or Proxy-holder(s).

(5) No gift or benefit in cash or kind shall be paid to the holders of equity securities in terms of Clause (c) of the Notification No. SEC/SRMI/2000-953/1950 dated 24th October, 2000 for attending the AGM of the Company.

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 8618220-1, Ext 10140

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

Paul Shackleton

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway

Victoria Foster Mitchell

Tel: +44 (0)20 7327 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.